Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.

International experts cooperating with the FDA have confirmed the efficacy and safety of eskatemine in treatment of unipolar, treatment-resistant depression, which might become the first cutting edge therapy for patients since the last innovation introduced 35 years ago. Celon Pharma develops this substance in two indications and is currently conducting phase II clinical trials. OnRead more »

Maciej Wieczorek on the strategies of developing innovative medicines at the 11th Multiciplinary conference on pharmaeutical science “Science for the Industry, Industry for science”

On 16 November this year,  President of the Management Board of Celon Pharma S.A. will give a lecture discussing the discovery and implementation of innovations in the pharmaceutical sector on the example of drug candidates developed under Celon Pharma’s clinical programmes. He will also participate in an expert debate entitled: “Business for science”. We encourageRead more »

Celon Pharma on the development of cancer drugs at the ORTC-NCI-AACR SYMPOSIUM

Aleksandra Stańczak, PhD, Leader of the Oncology Research Group will present results for two inhibitors under Celon Pharma’s development at the 30th symposium organised by European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and  American Association for Cancer Research (AACR), to be held on 13-16. November in Dublin. The followingRead more »

Celon Pharma at ESMO 2018

Representatives of the Oncology Research Group will take part in ESMO 2018, a congress organised by the European Society for Medical Oncology, which will be held on 19 October in Munich. In the course of the congress, they will present selected results of preclinical trials for the FGFR inhibitor at a poster session held onRead more »

The first stage of building Celon Pharma’s R&D Centre in Kazuń Nowy is on the home run and in line with the Company’s investment plan

Conclusion of the building shell stage was celebrated with symbolic topping out, which was carried out by representatives of Celon Pharma S.A. and  Skanska, the General Contractor, on 15 October.  The task commissioned by Celon Pharma includes general contracting of the building shell together with internal installation systems, roads and external area, as well asRead more »

Celon Pharma will present results of its research on esketamine and the PDE10A inhibitor at the 31st European College of Neuropsychopharmacology Congress in Barcelona

During the three days of the congress, more than 6,000 participants from all over the world: psychiatrists, psychologists and neurologists, will discuss the most important scientific reports in the field of diagnosis and treatment of brain diseases, from primary research to clinical development. Representatives of the Oncology Research Group will present three poster session topicsRead more »

Celon Pharma on Esketamine at the 3rd Central European Biomedical Congress (CEBC)

Representatives of the Celon Pharma Neuropsychiatry Research Group took part in the 3rd Central European Biomedical Congress (CEBC) which was held on 15-18 September this year. This is the largest scientific conference dedicated to preclinical research and biomedical sciences in our part of Europe. The theme of this year’s edition was, among others, neuropsychiatry. DuringRead more »

Celon Pharma enhances its platform for the development of biotechnology drugs

The company has established substantive cooperation with Pure Biologics S.A., a biopharmaceutical company. The two entities will cooperate in the field of research and development on biotechnological drugs, which will result in the identification of potential biotech drug candidates, which Celon Pharma will subsequently be developing in preclinical and clinical areas. Maciej Wieczorek, PhD, CEORead more »